Get started
Author

Hiroki Yukami

Observed names: H. Yukami, H., Yukami, HIROKI YUKAMI, Yukami Hiroki
ORCID: 0000-0001-7781-4609
Observed ORCID: 0000-0001-7781-4609
OpenAlex ID: A5043769434
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
2022 · Shogo Kumagai, Shohei Koyama, et al. · Cancer Cell · 905
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
2023 · Daisuke Kotani, Eiji Oki, et al. · Nature Medicine · 534
PDF
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
2024 · Yoshiaki Nakamura, Jun Watanabe, et al. · Nature Medicine · 290
CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
2021 · Hiroya Taniguchi, Yoshiaki Nakamura, et al. · Cancer Science · 162
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY
2024 · K. Kataoka, K. Mori, et al. · Annals of Oncology · 50
PDF
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
2022 · Hiroki Yukami, Akihito Kawazoe, et al. · Clinical Cancer Research · 24
Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.
2024 · Hiroki Yukami, Yoshiaki Nakamura, et al. · Journal of Clinical Oncology · 19
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration
2022 · Takao Morinaga, Takashi Inozume, et al. · Cancer Research Communications · 17
Long-term clinical outcomes of patients diagnosed with pT1a-muscularis mucosae with lymphovascular invasion or pT1b after endoscopic resection for cT1N0M0 esophageal squamous cell carcinoma
2021 · Tomohiro Kadota, Daiki Sato, et al. · Esophagus · 16
Emergence of Concurrent MultipleEGFRMutations andMETAmplification in a Patient WithEGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab
2020 · Yoshiaki Nakamura, Akinori Sasaki, et al. · JCO Precision Oncology · 15
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.
2023 · Eiji Oki, Daisuke Kotani, et al. · Journal of Clinical Oncology · 14
PDF
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy
2021 · Masaaki Miyo, Takeshi Kato, et al. · Cancer Science · 12
O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
2021 · H. Shirasu, H. Taniguchi, et al. · Annals of Oncology · 10
PDF
P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress)
2020 · H. Yukami, S. Mishima, et al. · Annals of Oncology · 10
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery
2025 · Koji Ando, Atsushi Hamabe, et al. · Annals of Surgery · 8
Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.
2021 · Hiroki Yukami, Yoshiaki Nakamura, et al. · Journal of Clinical Oncology · 7
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
2026 · Kozo Kataoka, Kazuma Ito, et al. · JAMA Oncology · 5
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
2022 · Takahiko Ito, Atsuo Takashima, et al. · International Journal of Clinical Oncology · 5
Postoperative circulating tumor DNA-based molecular residual disease in patients with BRAF V600E and MSI-H colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.
2023 · Jun Watanabe, Eiji Oki, et al. · JCO Global Oncology · 4
PDF
Definitive chemoradiotherapy has comparable survival outcomes to esophagectomy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: real-world data
2022 · Kentaro Sawada, Daisuke Kotani, et al. · International Journal of Clinical Oncology · 4
PDF
Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer
2021 · HIROYUKI KODAMA, TETSUJI TERAZAWA, et al. · In Vivo · 4
PDF
Impact of modified FOLFOX‐6 for patients with gastric cancer and a gastrointestinal obstruction
2018 · Hiroki Yukami, Tetsuji Terazawa, et al. · Asia-Pacific Journal of Clinical Oncology · 4
113TiP Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
2020 · H. Yukami, M. Saori, et al. · Annals of Oncology · 3
ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer
2025 · Hiroki Yukami, Toshifumi Yamaguchi, et al. · Future Oncology · 2
PDF
Factors associated with aggressive care at the end of life for patients with gastrointestinal cancer
2025 · Toru Kadono, Toshifumi Yamaguchi, et al. · Annals of Palliative Medicine · 2
Works count: 93
Citation count: 2,142
H-index: 12
I10-index: 14
Year
Topic
Type